VivoSim Labs, Inc. (NASDAQ:VIVS – Get Free Report) saw a large decline in short interest in June. As of June 15th, there was short interest totaling 19,972 shares, a decline of 40.1% from the May 31st total of 33,344 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 58,969 shares, the days-to-cover ratio is presently 0.3 days.
Institutional Investors Weigh In On VivoSim Labs
An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 8.23% of the company’s stock.
VivoSim Labs Trading Down 3.3%
VivoSim Labs stock traded down $0.04 during midday trading on Wednesday, reaching $1.03. The company’s stock had a trading volume of 45,787 shares, compared to its average volume of 855,817. The stock has a market cap of $2.70 million, a PE ratio of -0.33 and a beta of 1.38. VivoSim Labs has a 52 week low of $0.94 and a 52 week high of $5.30. The business has a 50-day moving average price of $1.28 and a 200-day moving average price of $1.69.
Analyst Ratings Changes
Get Our Latest Research Report on VivoSim Labs
About VivoSim Labs
VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.
The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.
Read More
- Five stocks we like better than VivoSim Labs
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
- Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push
- 3 Big Banks Plan Double Digit Dividend Increases After Passing Fed Stress Test
- 3 ETFs Offering Exposure to Latin America’s Stock Market Rally
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
